BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

258 related articles for article (PubMed ID: 21979894)

  • 1. Protein alterations associated with temozolomide resistance in subclones of human glioblastoma cell lines.
    Sun S; Wong TS; Zhang XQ; Pu JK; Lee NP; Day PJ; Ng GK; Lui WM; Leung GK
    J Neurooncol; 2012 Mar; 107(1):89-100. PubMed ID: 21979894
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inhibition of prolyl 4-hydroxylase, beta polypeptide (P4HB) attenuates temozolomide resistance in malignant glioma via the endoplasmic reticulum stress response (ERSR) pathways.
    Sun S; Lee D; Ho AS; Pu JK; Zhang XQ; Lee NP; Day PJ; Lui WM; Fung CF; Leung GK
    Neuro Oncol; 2013 May; 15(5):562-77. PubMed ID: 23444257
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hyperoxia resensitizes chemoresistant human glioblastoma cells to temozolomide.
    Sun S; Lee D; Lee NP; Pu JK; Wong ST; Lui WM; Fung CF; Leung GK
    J Neurooncol; 2012 Sep; 109(3):467-75. PubMed ID: 22763762
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeting miR-381-NEFL axis sensitizes glioblastoma cells to temozolomide by regulating stemness factors and multidrug resistance factors.
    Wang Z; Yang J; Xu G; Wang W; Liu C; Yang H; Yu Z; Lei Q; Xiao L; Xiong J; Zeng L; Xiang J; Ma J; Li G; Wu M
    Oncotarget; 2015 Feb; 6(5):3147-64. PubMed ID: 25605243
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Distinct molecular mechanisms of acquired resistance to temozolomide in glioblastoma cells.
    Happold C; Roth P; Wick W; Schmidt N; Florea AM; Silginer M; Reifenberger G; Weller M
    J Neurochem; 2012 Jul; 122(2):444-55. PubMed ID: 22564186
    [TBL] [Abstract][Full Text] [Related]  

  • 6. MALAT1 is a prognostic factor in glioblastoma multiforme and induces chemoresistance to temozolomide through suppressing miR-203 and promoting thymidylate synthase expression.
    Chen W; Xu XK; Li JL; Kong KK; Li H; Chen C; He J; Wang F; Li P; Ge XS; Li FC
    Oncotarget; 2017 Apr; 8(14):22783-22799. PubMed ID: 28187000
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long Non-Coding RNA MALAT1 Decreases the Sensitivity of Resistant Glioblastoma Cell Lines to Temozolomide.
    Li H; Yuan X; Yan D; Li D; Guan F; Dong Y; Wang H; Liu X; Yang B
    Cell Physiol Biochem; 2017; 42(3):1192-1201. PubMed ID: 28668966
    [TBL] [Abstract][Full Text] [Related]  

  • 8. ATM inhibitor KU-55933 increases the TMZ responsiveness of only inherently TMZ sensitive GBM cells.
    Nadkarni A; Shrivastav M; Mladek AC; Schwingler PM; Grogan PT; Chen J; Sarkaria JN
    J Neurooncol; 2012 Dec; 110(3):349-57. PubMed ID: 23054561
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Downregulation of BRCA1-BRCA2-containing complex subunit 3 sensitizes glioma cells to temozolomide.
    Chai KM; Wang CY; Liaw HJ; Fang KM; Yang CS; Tzeng SF
    Oncotarget; 2014 Nov; 5(21):10901-15. PubMed ID: 25337721
    [TBL] [Abstract][Full Text] [Related]  

  • 10. EFEMP1 induces γ-secretase/Notch-mediated temozolomide resistance in glioblastoma.
    Hiddingh L; Tannous BA; Teng J; Tops B; Jeuken J; Hulleman E; Boots-Sprenger SH; Vandertop WP; Noske DP; Kaspers GJ; Wesseling P; Wurdinger T
    Oncotarget; 2014 Jan; 5(2):363-74. PubMed ID: 24495907
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of aberrant p53 function on temozolomide sensitivity of glioma cell lines and brain tumor initiating cells from glioblastoma.
    Blough MD; Beauchamp DC; Westgate MR; Kelly JJ; Cairncross JG
    J Neurooncol; 2011 Mar; 102(1):1-7. PubMed ID: 20593219
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The DNA repair protein ALKBH2 mediates temozolomide resistance in human glioblastoma cells.
    Johannessen TC; Prestegarden L; Grudic A; Hegi ME; Tysnes BB; Bjerkvig R
    Neuro Oncol; 2013 Mar; 15(3):269-78. PubMed ID: 23258843
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inhibition of GSH synthesis potentiates temozolomide-induced bystander effect in glioblastoma.
    Kohsaka S; Takahashi K; Wang L; Tanino M; Kimura T; Nishihara H; Tanaka S
    Cancer Lett; 2013 Apr; 331(1):68-75. PubMed ID: 23246370
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Temozolomide-modulated glioma proteome: role of interleukin-1 receptor-associated kinase-4 (IRAK4) in chemosensitivity.
    Kumar DM; Patil V; Ramachandran B; Nila MV; Dharmalingam K; Somasundaram K
    Proteomics; 2013 Jul; 13(14):2113-24. PubMed ID: 23595970
    [TBL] [Abstract][Full Text] [Related]  

  • 15. HB-EGF is associated with DNA damage and Mcl-1 turnover in human glioma cell lines treated by Temozolomide.
    Séry Q; Rabé M; Oliver L; Vallette FM; Gratas C
    Biochem Biophys Res Commun; 2017 Dec; 493(4):1377-1383. PubMed ID: 28970067
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Gene expression profiling predicts response to temozolomide in malignant gliomas.
    Yoshino A; Ogino A; Yachi K; Ohta T; Fukushima T; Watanabe T; Katayama Y; Okamoto Y; Naruse N; Sano E; Tsumoto K
    Int J Oncol; 2010 Jun; 36(6):1367-77. PubMed ID: 20428759
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The histone demethylase KDM5A is a key factor for the resistance to temozolomide in glioblastoma.
    Banelli B; Carra E; Barbieri F; Würth R; Parodi F; Pattarozzi A; Carosio R; Forlani A; Allemanni G; Marubbi D; Florio T; Daga A; Romani M
    Cell Cycle; 2015; 14(21):3418-29. PubMed ID: 26566863
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Synergistic Suppression of Glioblastoma Cell Growth by Combined Application of Temozolomide and Dopamine D2 Receptor Antagonists.
    Liu Z; Jiang X; Gao L; Liu X; Li J; Huang X; Zeng T
    World Neurosurg; 2019 Aug; 128():e468-e477. PubMed ID: 31048057
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bak and Mcl-1 are essential for Temozolomide induced cell death in human glioma.
    Gratas C; Séry Q; Rabé M; Oliver L; Vallette FM
    Oncotarget; 2014 May; 5(9):2428-35. PubMed ID: 24811082
    [TBL] [Abstract][Full Text] [Related]  

  • 20. IKBKE enhances TMZ-chemoresistance through upregulation of MGMT expression in glioblastoma.
    Guo G; Sun Y; Hong R; Xiong J; Lu Y; Liu Y; Lu J; Zhang Z; Guo C; Nan Y; Huang Q
    Clin Transl Oncol; 2020 Aug; 22(8):1252-1262. PubMed ID: 31865606
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.